Edgington; Thomas S.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Edgington; Thomas S..The latest application filed is for "targeted delivery to legumain-expressing cells".

Company Profile

0.18.5

Edgington; Thomas S. - La Jolla CA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Targeted delivery to legumain-expressing cells App 20100113328 - Liu; Cheng ; et al.	2010-05-06
Combined methods for tumor coagulation and tumor treatment Grant 7,691,380 - Thorpe , et al. April 6, 2	2010-04-06
Targeted delivery to legumain-expressing cells Grant 7,608,591 - Liu , et al. October 27, 2	2009-10-27
Targeted thrombosis Grant 7,399,743 - Liu , et al. July 15, 2	2008-07-15
Peptides That Bind To Atherosclerotic Lesions App 20070264194 - Liu; Cheng ; et al.	2007-11-15
Targeted delivery to legumain-expressing cells App 20060135410 - Liu; Cheng ; et al.	2006-06-22
Combined methods and compositions for coagulation and tumor treatment Grant 6,749,853 - Thorpe , et al. June 15, 2	2004-06-15
Combined methods and compositions for coagulation and tumor treatment App 20030219441 - Thorpe, Philip E. ; et al.	2003-11-27
Targeted thrombosis App 20030194400 - Liu, Cheng ; et al.	2003-10-16
Methods and compositions for the specific coagulation of vasculature Grant 6,093,399 - Thorpe , et al. July 25, 2	2000-07-25
Kits and methods for the specific coagulation of vasculature Grant 6,036,955 - Thorpe , et al. March 14, 2	2000-03-14
Methods for the specific coagulation of vasculature Grant 6,004,555 - Thorpe , et al. December 21, 1	1999-12-21
Human mutant tissue factor compositions useful as tissue factor antagonists Grant 5,994,296 - Ruf , et al. November 30, 1	1999-11-30
Tissue factor compositions and ligands for the specific coagulation of vasculature Grant 5,877,289 - Thorpe , et al. March 2, 1	1999-03-02
Human mutant tissue factor compositions useful as tissue factor antagonists Grant 5,726,147 - Ruf , et al. March 10, 1	1998-03-10
Human tissue factor related DNA segments, polypeptides and antibodies Grant 5,622,931 - Edgington , et al. April 22, 1	1997-04-22
Inhibition of Mac-1 receptor binding to fibrinogen using D.sub.30 homologs Grant 5,473,051 - Altieri , et al. December 5, 1	1995-12-05
Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor Grant 5,437,864 - Edgington , et al. August 1, 1	1995-08-01
Human tissue factor related DNA segments Grant 5,110,730 - Edgington , et al. May 5, 1	1992-05-05
Substantially pure cytotoxicity triggering factor Grant 4,785,077 - Kornbluth , et al. November 15, 1	1988-11-15
Diagnostic assay for the presence of apolipoproteins associated with plasma high density lipoproteins Grant 4,677,057 - Curtiss , et al. June 30, 1	1987-06-30
Carcinoembryonic antigen isomer Grant 4,145,336 - Edgington , et al. March 20, 1	1979-03-20
Diagnostic method and reagent Grant 4,140,753 - Edgington , et al. February 20, 1	1979-02-20

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.